Get the Stockscreener App
28.79
4.01%
1.11
After Hours:
28.79
Agios Pharmaceuticals Inc stock is traded at $28.79, with a volume of 648.16K.
It is up +4.01% in the last 24 hours and up +4.46% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
See More
Previous Close:
$27.68
Open:
$28.12
24h Volume:
648.16K
Relative Volume:
0.63
Market Cap:
$1.71B
Revenue:
$66.05M
Net Income/Loss:
$-422.60M
P/E Ratio:
-3.9705
EPS:
-7.251
Net Cash Flow:
$-384.73M
1W Performance:
-5.36%
1M Performance:
+4.46%
6M Performance:
+4.96%
1Y Performance:
-15.40%
1-Day Range:
$27.93
$29.32
1-Week Range:
$26.44
$30.28
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
28.79 | 1.65B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
441.74 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
628.73 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
842.27 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.64 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.69 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Reiterated | H.C. Wainwright | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
AGIO secures global rights to late-stage rare blood disorder candidate - MSN
How The Tebapivat Setback Is Reframing The Story For Agios Pharmaceuticals (AGIO) - Yahoo Finance
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate - TradingView
Trading the Move, Not the Narrative: (AGIO) Edition - Stock Traders Daily
Agios inks global licensing agreement with Oscotec - The Pharma Letter
Oscotec Signs Up to $665 Million Licensing Deal with Agios Pharmaceuticals for Autoimmune Drug Candidate Cevidoplenib - 알파경제
Agios Halts Tebapivat Trials As Sickle Cell Focus Shapes Valuation - Sahm
Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib - Yahoo Finance
Agios scraps blood cancer drug program after study miss - AOL.com
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - The Globe and Mail
AGIO: Cevidoplenib licensed for ITP, with strong phase II data and phase III planned for 2028 - TradingView
Agios licenses oral SYK inhibitor for rare blood disorder By Investing.com - Investing.com South Africa
Agios Pharmaceuticals (AGIO) Forms Licensing Deal for Cevidoplen - GuruFocus
AGIO: Exclusive global license for cevidoplenib expands rare hematology pipeline and targets ITP - TradingView
Agios licenses oral SYK inhibitor for rare blood disorder - Investing.com UK
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib - The Manila Times
Agios Pharmaceuticals Secures Exclusive Global Rights to Next-Generation SYK Inhibitor Cevidoplenib for Immune Thrombocytopenia Treatment - Quiver Quantitative
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize ... - Caledonian Record
Rare blood disorder drug deal gives Agios shot at $1B U.S. sales - Stock Titan
Oscotec licenses autoimmune drug to US Agios in deal up to 1 trillion wonCHOSUNBIZ - Chosunbiz
AGIO Stock Price, Quote & Chart | AGIOS PHARMACEUTICALS INC (NASDAQ:AGIO) - ChartMill
Agios halts tebapivat development for blood disorder - Investing.com UK
AGIO Maintained by B of A Securities -- Price Target Lowered to $40 - GuruFocus
Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class - Seeking Alpha
Agios Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $40.88, Implies 34% Upside - TradingView
Agios Pharmaceuticals (AGIO) Discontinues Myelodysplastic Syndro - GuruFocus
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report? - Yahoo Finance
Agios halts tebapivat development for blood disorder By Investing.com - Investing.com South Africa
Agios slides after discontinuing development of tebapivat in myelodysplastic syndromes (AGIO) - Yahoo Finance
Allogene CEO to step down; Agios drug fails key test - BioPharma Dive
Agios provides update on phase 2b trial of tebapivat in lower-risk myelodysplastic syndromes - marketscreener.com
Agios to drop myelodysplastic syndromes drug (AGIO:NASDAQ) - Seeking Alpha
Agios Pharmaceuticals (AGIO) Halts Tebapivat Development for Low - GuruFocus
Agios Pharmaceuticals stock tumbles on trial setback By Investing.com - Investing.com Canada
Agios Pharmaceuticals stock tumbles on trial setback - Investing.com
Agios scraps blood disorder drug program after study miss - marketscreener.com
Agios to stop tebapivat in LR-MDS, plans sickle cell data in 2H 2026 - Stock Titan
Here's Why Agios Pharmaceuticals Crashed 23% Today - AOL.com
Agios Pharmaceuticals (AGIO) Surges 6.3% as Stock Approaches Key Resistance LevelCall Resistance - thelegaladvocate.com
Agios announces Pyrukynd approval in the EU - The Pharma Letter
Analysts Offer Insights on Healthcare Companies: Clinuvel Pharmaceuticals (OtherCLVLF) and Agios Pharma (AGIO) - The Globe and Mail
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - The Globe and Mail
Agios Pharmaceuticals Gains EU Approval for PYRUKYND in Adult Thalassaemia - World Business Outlook
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - afp.com
Agios, Partner von Avanzanite Bioscience, gibt die Zulassung von PYRUKYND® (Mitapivat) in der Europäischen Union für Erwachsene mit Thalassämie bekannt - The Joplin Globe
Agios Pharmaceuticals (AGIO) Secures EU Approval for PYRUKYND - GuruFocus
EU approves mitapivat for thalassaemia treatment in adults - Investing.com UK
EU approves mitapivat for thalassaemia treatment in adults By Investing.com - Investing.com Nigeria
Avanzanite Bioscience's partner Agios announces Pyrukynd® (mitapivat) approval in EU - marketscreener.com
Agios Gets EU Approval for Pyrukynd in Thalassemia - Moomoo
New oral thalassemia drug PYRUKYND approved for adults in EU - Stock Titan
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.89%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):